Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Node Positive Breast Cancer
Interventions: PROCEDURE: 6 TEC q 3 weeks|PROCEDURE: 4 EC q 2 weeks followed by 4 TXT q 2 weeks|PROCEDURE: 4 TXT q 2 weeks followed by 4 EC q 2 weeks
Sponsor: Association Européenne de Recherche en Oncologie
Collaborators: Aventis Pharmaceuticals|Amgen